Deprexis® - mild to severe symptoms of depression
|Technology||GAIA´s proprietary artificial intelligence (AI)-expert system, broca®|
|Indication||Symptoms of mild to severe depression|
|Period of use||3 months|
|Commercial rights||US market|
|Key advantages||• Based on Cognitive Behavioral Therapy
• Strong clinical evidence
• Highly individualized
• To be used standalone or as a complement to traditional pharma treatments
Deprexis® is a fully automated digital therapy developed by Orexo´s partner GAIA and is based on its proprietary artificial intelligence (AI)-expert system, broca®. Deprexis® can be used to manage symptoms of mild to severe depression.
Depression is a leading cause of disability around the world and contributes greatly to the global burden of mental health illness. In the US, an estimated number of 17.3 million adults had at least one major depressive episode corresponding to 7.1 percent of all US adults.1
About 20 percent of Americans with an anxiety or mood disorder, such as depression, also have a substance abuse disorder.2 With respect to opioid use disorder, Orexo´s own retrospective data from the REZOLV study (2016), showed over 30 percent of patients were diagnosed with co-existing depressive disorder.
Deprexis® is the world’s most researched digital therapy program for depression. Proven effectiveness in 11 RCTs with an NNT of 3.6.
Effective depression treatment
Nine independent studies conducted with deprexis® have demonstrated its effectiveness as a standalone treatment and have confirmed the increase in benefits when deprexis® is added to existing care plans.
Effective treatment of comorbid depression
Depression is especially prevalent in patients with severe medical conditions and disorders. Deprexis® has been shown to effectively treat depression as a comorbidity of epilepsy, multiple sclerosis and gambling disorder.
Proven cost reduction
A study of 3,805 participants demonstrated using deprexis® significantly reduces the cost of treating depression for health insurers, while simultaneously reducing depressive symptoms and increasing quality of life in patients.
Gräfe et al. (2020)